Table 1.

Baseline characteristics, complications, concomitant medications and management of patients in the simulated cohort

Patient demographics	Mean	sd	References
Sex (% male)	53.4	—	[22]
Mean age (years)	37.8	—	[22]
Duration of diabetes (years)	10.4	—	[22]
BMI (kg/m2)	25.6	—	[22]
Ethnic origin (%)
Caucasian	93.5	—	[32]
Black	2	—	[32]
Hispanic	0	—	[32]
Native American	0	—	[32]
Asian	4.5	—	[32]
Risk factors
Glycated haemoglobin (HbA1c) (%)	9.4	2.10	[25]
Systolic blood pressure (mmHg)	132	21.00	[25]
Total cholesterol (mmol/l)	5.4	—	[25]
High-density lipoproteincholesterol (mmol/l)	1.5	—	[25]
Low-density lipoproteincholesterol (mmol/l)	3.2	—	[25]
Triglycerides (mmol/l)	1.2	—	[25]
Proportion of smoker (%)	16.4	—	[25]
Pre-existing complications
Myocardial infarction (%)	1.7		[22]
Peripheral vascular disease (%)	1.6		[22]
Stroke (%)	2.2		[22]
Heart failure (%)	0.5		[22]
Microalbuminuria (%)	20		[25]
Background diabeticretinopathy (%)	27.46		[25]
Neuropathy (%)	9.88		[25]
Patient management
Taking aspirin (%)	4.3		[26]
Taking statins (%)	17.8		[27]
Taking ACE-I (%)	14.6		[28,29]
Screened for retinopathy (%)	63.2		[31]
Screened for renal disease (%)	60		[30]

ACE-I, angiotensin converting enzyme inhibitor; BMI, body mass index; sd, standard deviation.